PharmaCyte Biotech Inc (PMCB)

[Peacefulwendy]

PharmaCyte Biotech is Making Waves - Take the Hint (PMCB)

PharmaCyte Biotech Inc. (OTCMKTS:PMCB) is turning more and more heads. There has to be a reason, but more than that, there's apt to be a beneficial effect on the stock's price.Anybody who owns, or is thinking about owning, a stake in PharmaCyte Biotech Inc. (OTCMKTS:PMCB) will want to take a closer look at not one but two different news items that were posted today. One of them could be an important housekeeping item, and the other one is encouraging, though not for the reason it may seem on the surface.

For the unfamiliar, PharmaCyte Biotech is the developer of a novel drug-delivery technology called Cell-in-a-Box. Just as the trademarked name describes, this biotechnology puts living cells grown to perform a specific function into a container... about the size of the head of the pin. The "shell" is porous enough to let chemicals in and waste out, but not so porous that it allows a body's immune system to attack and kill the foreign cells. The show-stopper, however, is the durability of the Cell-in-a-Box capsules. They are designed to last indefinitely.

The end result is the ability to make certain cells and place them inside a body.

To date PharmaCyte Biotech has focused on using the Cell-in-a-Box platform to treat pancreatic cancer, and more recently it's beginning to develop a therapy for type 1 diabetes. In fact, with the ability to encapsulate insulin-producing cells, PMCB may well have the equivalent to a cure for debates. The company also has brain tumors on the radar, with the potential use of cannabinoids as the basis for the therapy. The sky's the limit, however, for how the biotechnology can be used.

Fast forward to today.

Though it won't affect the price of the stock or mean much in terms of the company's R&D, PharmaCyte will be using a new stock transfer agent as of tomorrow. The America Stock Transfer and Trust Company will be taking on those duties after today.

The other news from PharmaCyte Biotech today - news that might actually move the price of PMCB - is that it's now being given analytical coverage from SmallCap IR.

It's often an overlooked reality regarding small and micro cap companies, but one of the toughest challenges these outfits have is getting professional and retail investors to notice them. PMCB is being increasingly noticed, however, which is a good sign. And, the more it gets noticed, the easier it becomes for another to notice it. In that light, PharmaCyte Biotech may be about to hit a publicity critical mass.

To the extent it matters (which is quite a bit), SmallCap IR wasn't paid a penny by anyone to open its coverage of PMCB. Better yet, it initiated coverage with a buy rating. To read the report, visitors can go here: https://secure.blueoctane.net/forms/P8HV6VHHUN6N

With or without the SmallCap IR analytical coverage, though, PharmaCyte Biotech Inc. is quickly turning into one of the market's more compelling story stocks. It was also a big hit at the BIO International Convention in June, as well as at the Astrodrugs conference.

For more on Pharmacyte Biotech, visit the company website here.

http://www.smallcapnetwork.com/PharmaCyte-Biotech-is-Making-Waves-Take-the-Hint-PMCB/s/via/10/article/view/p/mid/3/id/554/